EMEA-001679-PIP01-14
Key facts
| Active substance |
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0356/2022
|
| PIP number |
EMEA-001679-PIP01-14
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|